Live Online Seminar on October 8th, 2024:

"MASH Pharmacotherapy - On the Brink of a New Era"

Our next complimentary on-demand online seminar Dr.Hans de Vries, one of our Lead Scientists, will discuss the latest developments in the non-invasive diagnosis and pharmacological therapy for Metabolic Associated SteatoHepatitis (MASH). 

Profil Banner 2021_04_live2-1

The live online seminar will take place on October 08th, 2024 at

04:00pm CEST 

07:00am PST

10:00am ET

 

Watch this educational online seminar and benefit by:

  • Exploring the epidemiology and basic pathophysiology of MAFLD and MASH
  • Gaining insight in imaging and non-invasive diagnostic scoring systems for MASH
  • Understanding the regulatory pathway for MASH therapies
  • Learning about new treatment options, such as GLP-1 based drugs, T3beta-agonists, FGF-21 agonists

 

Online seminar synopsis

Metabolic associated Fatty Liver Disease affects around 1 in five people living around the world. A small but distinct percentage develops steatohepatitis (MASH). When significant fibrosis then comes into play, risk for mortality and liver events increase. Recently the first drug for MASH received FDA approval. This also renews the interest in non-invasive diagnostic methods, which don’t require a liver biopsy. Finally, new drugs with high efficacy are in late stage of development. All this and more will be discussed during this online seminar. 

 

 

For whom:

  • Clinical researchers and professionals
  • Pharmaceutical company representatives
  • Policy makers and regulators
  • Academic researchers and institutions
  • Anyone interested in MAFLD and MASH

 

Meet the presenter

Dr. Hans de Vries obtained board licenses in Internal Medicine and Endocrinology at the VU University Medical Centre, Amsterdam. He was a professor of Internal Medicine at the University of Amsterdam's Faculty of Medicine from 2016 to 2023. Having joined Profil as of 2017, he maintains his academic position for one day per week. Dr. de Vries has been Principal Investigator in numerous clinical trials and has published more than 250 peer-reviewed scientific publications. He is a frequently invited speaker at international diabetes meetings, and has been a editorial board member of Diabetes Care, the Journal of Diabetes Science and Technology, and International Associate Editor of Diabetes Technology & Therapeutics.

Share this online seminar with your colleagues: